UroGen Pharma Ltd
URGNHealthcare|Biotechnology|USA
$38.57
-1.67 (-4.15%)
Clinical Trials (20)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06774131 A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma | P3 | Recruiting | 70 | Open-label | UGN-104 |
| NCT06331299 A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer | Bladder Cancer, Urothelial Carcinoma | P3 | Active | 99 | Open-label | UGN-103 |
| NCT05243550 A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | Bladder Cancer, Urothelial Carcinoma | P3 | Active | 240 | Open-label | UGN-102 |
| NCT05874921 uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | Urothelial Carcinoma, Urothelial Carcinoma Recurrent | Recruiting | 400 | — | Jelmyto (mitomycin) for pyelocalyceal solution | |
| NCT02793128 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study | Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis | P3 | Completed | 71 | Open-label | UGN-101 instillations |
| NCT05136898 Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) | Bladder Cancer, Urothelial Carcinoma | P3 | Completed | 8 | Open-label | UGN-102 |
| NCT04688931 A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | Bladder Cancer, Urothelial Carcinoma | P3 | Terminated | 282 | RCT, Open-label | UGN-102 |
| NCT04006691 Efficacy and Safety of UGN-101 in Recurrent Patients | Carcinoma, Transitional Cell Carcinoma | P3 | Withdrawn | — | Open-label | UGN-101 instillations |
| NCT02179099 Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients | Overactive Bladder | P1P2 | Terminated | 3 | Open-label | — |
| NCT03558503 A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | Bladder Cancer, Urothelial Carcinoma | P2 | Completed | 63 | Open-label | UGN-102 |
| NCT02674269 Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") | Overactive Bladder | P1P2 | Withdrawn | — | RCT, Double-blind | 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml) |
| NCT01997983 Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients | Interstitial Cystitis, IC | P1P2 | Completed | 15 | Open-label | — |
| NCT02307487 Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | Bladder Cancer, Neoplasms | P2 | Completed | 14 | Open-label | 120 mg MMC in 90ml gel, 140 mg MMC in 90ml gel, 160 mg MMC in 90ml gel, 120 mg MMC in 60ml gel, 140 mg MMC in 60ml gel, 160 mg MMC in 60ml gel |
| NCT05375903 A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | Non-muscle Invasive Bladder Cancer, NMIBC | P1 | Completed | 51 | Open-label | UGN-301, UGN-201, Gemcitabine |
| NCT01648010 Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer | Carcinoma of Urinary Bladder, Invasive | N/A | Completed | 7 | Open-label | — |
| NCT05494411 Named Patient Program for Mitomycin for Pyelocalyceal Solution | Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter | AVAILABLE | — | — | Mitomycin for pyelocalyceal solution | |
| NCT02891460 Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients | Urinary Bladder Neoplasms, Urologic Neoplasms | N/A | Completed | 18 | Open-label | — |
| NCT01803295 Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC | Carcinoma of Urinary Bladder, Superficial | N/A | Completed | 80 | RCT, Open-label | — |
| NCT02701023 Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma | Urothelial Carcinoma Ureteral Location | NO_LONGER_AVAILABLE | — | — | MitoGel | |
| NCT01799499 A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) | Non Muscle Invasive Bladder Cancer | N/A | Withdrawn | — | RCT, Open-label | — |